Results 171 to 180 of about 7,283,036 (268)

Key-Informant Perspectives On Pharmacy-Based Methadone Treatment For Opioid Use Disorder In The US. [PDF]

Health Aff (Millwood)
Stewart MT, Feltus SR, Tschampl CA, Bratberg JP, Green TC.   +4 more
europepmc   +1 more source

What's in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment. [PDF]

J Gen Intern Med, 2023
Gazzola MG, Maclean E, Beitel M, Carmichael ID, Cammack KM, Eggert KF, Roehrich T, Madden LM, Jegede O, Zheng X, Bergman E, Barry DT.   +11 more
europepmc   +1 more source

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, Volume 121, Issue 11, Page 3010-3024, November 2026.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source

Where Do Clients Receive Methadone Treatment? Exploring Bypassing Behaviors in Methadone Treatment Clients: Temporal, Geographic, and Demographic Factors. [PDF]

Subst Use
Alibrahim A, Marsh JC, Amaro H, Kong Y, Khachikian T, Guerrero E.   +5 more
europepmc   +1 more source

Overdose reversal through peer intervention: Findings from the naloxone prospective outcome research study (NalPORS) on the effectiveness of overdose response by people who use opioids in the United Kingdom and Sweden

Addiction, Volume 121, Issue 11, Page 3025-3039, November 2026.
Abstract Background/aims Take‐home naloxone (THN) programmes have been introduced in many European countries to provide non‐medically trained people who are likely to witness an opioid overdose, including people who use opioids, with a naloxone kit and training.
Nicola Metrebian, Teodora Dascal, Clare Mackie, Rose Tinch‐Taylor, Ben Carter, Joanne Neale, Mariana Gonzalez Utrilla, Ed Day, Joar Guterstam, Kirsten Horsburgh, Martin Kåberg, Mike Kelleher, Soraya Mayet, Josie Smith, Desiree Eide, Elin Holmén, Rebecca McDonald, Stephen Parkin, Henrik Thiesen, John Strang, NalPORS Research Team, Dean Acreman, Shabana Akhtar, Louise Aitken, Martin Anderson, James Cassidy, Sarah Cosgrove, Jo Grayer, Michelle Hughes, Louise Horn, Anika Miah, John Pratt   +31 more
wiley   +1 more source

The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review. [PDF]

Pharmaceuticals (Basel)
Recarey-Rama S, Gómez-Trigo J, Gil-Rodriguez A, Dominguez E, Sánchez-Martínez I, Riveiro-Recimil Á, Barral-Raña A, de Leon J, Rodriguez-Viyuela A, Arrojo M, Carracedo A, Maroñas O.   +11 more
europepmc   +1 more source

Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation

Addiction, Volume 121, Issue 11, Page 3040-3052, November 2026.
Abstract Aims To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative ...
Vivienne Y. Zhou, Nadia Fairbairn, Jingxin Lei, Rupinder Brar, Paxton Bach, M. Eugenia Socias   +5 more
wiley   +1 more source

'It wasn't to get high; it was just to get by': experiences of patients who use fentanyl during methadone treatment and opportunities for improving care in Vermont and New Hampshire. [PDF]

Harm Reduct J
Boggis JS, Saunders EC, Marsch LA, Gallant T, Wolff K, Bryer C, Fowler R, Goodman DJ.   +7 more
europepmc   +1 more source

Veterans Health System Leader and Clinician Perspectives on Expanding Access to Methadone Treatment for Opioid Use Disorder. [PDF]

J Addict Med
Rahim F, Vanneman ME, Tuckett S, Zickmund SL, Gordon AJ, Jones AL, Nelson RE, Schlechter CR.   +7 more
europepmc   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

The American Journal on Addictions, Volume 35, Issue 6, Page 702-726, November 2026.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas, Matthew E. Sloan, Yaoyi Xing, Ethan Kim, Dhvani Mehta, Anna Mouzenian, Lena C. Quilty, Jeffrey D. Wardell, Shannon Lange, Daniel Felsky, Victor M. Tang   +10 more
wiley   +1 more source